Rivaroxaban Outmatched by VKAs for AF in Rheumatic Heart Disease

A striking and unexpected reduction in death with the use of predominantly warfarin was just one of the many surprises delivered by the INVICTUS trial at ESC 2022.
Medscape Medical News

source https://www.medscape.com/viewarticle/979861?src=rss